Month: April 2017

The Canadian Cancer Action Network (CCAN) is pleased to notify our 118 member organizations from across Canada of the launch of the 2017 Board of Directors recruitment and election process today, April 25, 2017. CCAN’s Recruitment Committee is currently seeking applications to fill several Director positions. At this time, we are specifically searching for candidates with experience and expertise in issues facing cancer patients, caregivers

— New estimate uncovers a modest investment into the province’s cancer system could eliminate financial hardship for patients — HALIFAX, April 26, 2017 /CNW/ – The McNeil Government has the opportunity to eliminate the financial hardship and related stress patient experience when they require cancer medications taken at home with a modest investment of less than $2 million dollars. Canada’s Western provinces all treat take-home

This spring, British Columbians are heading to the polls. As over 202,000 Canadians are diagnosed with cancer every year, including an estimated 25,600 new cases diagnosed in British Columbia, with approximately 10,100 dying of cancer each year. The government of British Columbia has an important role to play in making sure that everyone diagnosed with cancer has timely access to cancer care and essential medical

Research is vital to finding better ways to improve the health and quality of life for people living with frailty. This study, the Canadian Frailty Priority Setting Partnership, aims to identify priority areas for Canadian researchers and research funding organizations. To do this, the study is asking Canadians what they believe are the important questions related to care, support and treatment for frail older adults.

Researchers are taking big strides toward making prostate cancer treatment more personal — in other words, care that’s uniquely, specifically tailored to an individual and their cancer. Watch this short video from Dr. Alexander Wyatt and learn how his research provides hope for a new way to identify men with prostate cancer who will not respond well to hormone therapy early, so they can be

For years, researchers have been looking for new options for patients with advanced pancreatic cancer whose disease has progressed after receiving first-line treatments. ONIVYDE provides hope and a new treatment option for patients battling this disease. Canadian patients and caregivers have the opportunity to provide input to the panCanadian Oncology Drug Review (pCODR), the agency that will recommend (or not) whether ONIVYDE (irinotecan liposome injection)